Table 3 Univariate and multivariate analyses for progression-free survival.
Variables | Category | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | ||
Age, years | ≥ 65 (vs. < 65) | 0.92 | 0.62–1.37 | 0.687 | |||
Sex | Male (vs. female) | 0.77 | 0.51–1.15 | 0.203 | |||
ECOG PS | ≥ 1 (vs. 0) | 1.75 | 1.14–2.69 | 0.009 | 1.59 | 1.01–2.48 | 0.044 |
Histology | Diffuse (vs. intestinal) | 1.24 | 0.83–1.86 | 0.292 | |||
History of gastrectomy | Yes (vs. no) | 1.00 | 0.66–1.50 | 0.985 | |||
Lymph node metastasis | Yes (vs. no) | 0.90 | 0.60–1.34 | 0.589 | |||
Liver metastasis | Yes (vs. no) | 0.97 | 0.64–1.46 | 0.869 | |||
Peritoneal metastasis | Yes (vs. no) | 1.58 | 1.05–2.36 | 0.027 | 1.44 | 0.94–2.19 | 0.091 |
Number of metastatic sites | ≥ 2 (vs. 1) | 1.34 | 0.88–2.05 | 0.173 | 1.40 | 0.92–2.14 | 0.119 |
Number of prior chemotherapeutic regimens | ≥ 3 (vs. 1–2) | 0.79 | 0.45–1.37 | 0.399 | |||
Duration of prior ramucirumab | ≥ 3 months (vs. < 3 months) | 0.79 | 0.52–1.21 | 0.284 | |||
Ramucirumab-free interval | ≥ 3 months (vs. < 3 months) | 0.68 | 0.45–1.04 | 0.074 | 0.81 | 0.52–1.27 | 0.358 |
Anti-PD-1 inhibitor-free interval | < 60 days (vs. ≥ 60 days) | 0.91 | 0.61–1.35 | 0.623 | |||
Chemotherapy | FTD/TPI plus ramucirumab (vs. FTD/TPI) | 0.52 | 0.34–0.79 | 0.002 | 0.61 | 0.39–0.95 | 0.030 |
